platinum doublet
Recently Published Documents


TOTAL DOCUMENTS

156
(FIVE YEARS 76)

H-INDEX

15
(FIVE YEARS 6)

2022 ◽  
Vol 11 ◽  
Author(s):  
Tejas Patil ◽  
Yunan Nie ◽  
Dara L. Aisner ◽  
David Ross Camidge

Pemetrexed (used as a platinum doublet or as a maintenance regimen) is an established therapy for patients with advanced non-squamous non-small-cell lung cancer (NSCLC). In addition, certain gene rearrangements (e.g., ALK, ROS1, RET) appear to especially benefit from the use of pemetrexed. Inferior outcomes with pemetrexed compared to other chemotherapies in patients with NSCLC demonstrating squamous histology removed these patients from the labeled indication for the drug. While most squamous cases do not harbor driver oncogenes, rare exceptions exist. Whether the poor outcomes with pemetrexed extend to NSCLC with squamous component harboring driver oncogenes remains unexplored. In this case series, we describe two patients with adenosquamous histology harboring an ROS1 and ALK gene arrangement, respectively, who derived significant benefit from pemetrexed-based therapy. These cases suggest that the value of pemetrexed may need to be re-explored in adenosquamous NSCLC harboring such alterations.


2021 ◽  
Author(s):  
Toshiaki Takahashi ◽  
Kazuko Sakai ◽  
Hirotsugu Kenmotsu ◽  
Kiyotaka Yoh ◽  
Haruko Daga ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document